Khosla Impact

Khosla Impact, established in 2013, is an impact investment firm based in Menlo Park, California. It focuses on assisting high-impact entrepreneurs who develop products and services for the three billion people at the bottom of the world's economic pyramid. The firm invests in for-profit enterprises serving low-income individuals and small businesses in emerging markets, with a primary focus on South Asia. Khosla Impact encourages experimentation and supports entrepreneurs passionate about solving socio-economic challenges through technology and innovative business models.

Alex Bentley

Partner and Investor

Ryno Blignaut

Operating Partner

Alice Brooks

Principal

Peter Buckland

General Partner and COO

Brian Byun

Operating Partner

Catherine Casuga

Operating Partner

Ardy Daie

Operating Partner

Bryan Gartner

Partner

Kanu Gulati

Partner

Judy Huang

Operating Partner

Jun Jeon

Principal

Samir Kaul

Founding Partner and Managing Director

Vinod Khosla

Managing Director

Kelly Kinnard

Operating Partner

Nicholas Moryl

Associate

Keith Rabois

Managing Director

Arash Rebek

Partner, Capital Formation

Jessy Rivest

Partner and Investor

Jai Sajnani

Partner

Jai Sajnani

Partner and Investor

Leah Scanlan

Operating Partner

Nikita Shamgunov

Partner and Investor

Sven Strohband

Managing Director

Rajesh Swaminathan

Partner and Investor

Adina Tecklu

Partner and Investor

David Weiden

Managing Director

Reze Wong

Partner

Adam Coates

Operating Partner

Kanupriya Gulati Ph.D

Partner and Investor

Past deals in Medical Devices

Aktiia

Series B in 2025
Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

Overture Life

Venture Round in 2025
Overture Life, Inc. is a biotechnology company established in 2017 and headquartered in New York, New York. The company specializes in developing robotic technology and medical devices aimed at automating the in vitro fertilization (IVF) process. Overture Life's innovations include novel embryo testing methodologies and automated cryopreservation services, which help fertility clinics identify viable embryos prior to implantation. By streamlining the IVF process, Overture Life aims to make artificial insemination more accessible, reduce costs, optimize resource use, and improve success rates for practitioners and patients alike.

Clear Labs

Series D in 2025
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dxâ„¢ and Clear Safetyâ„¢, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Synex Medical

Series A in 2024
Synex Medical specializes in non-invasive blood testing technology, focusing on the development of a portable device that enables users to monitor metabolite concentrations without penetrating the skin. Utilizing a miniaturized magnetic resonance system, the company can accurately detect critical blood metabolites such as glucose, lactate, and ketones. This innovative approach employs only magnets and radio waves, ensuring there are no adverse health effects associated with its use. By providing precise information about metabolic health, Synex Medical aims to empower individuals to take proactive steps in managing their health and well-being.

Openwater

Venture Round in 2024
Openwater is a San Francisco-based startup founded in 2016 that focuses on developing advanced medical technology aimed at diagnosing and treating diseases at the cellular level. The company has created a wearable device that leverages novel optoelectronic technology to offer high-resolution imaging capabilities, effectively replacing traditional MRI methods. By utilizing LCDs with small pixels, Openwater's device generates holographic images that minimize scattering and achieve MRI-like resolution. This innovation enables physicians to diagnose and treat diseases by targeting individual cells while preserving the surrounding tissue, thereby enhancing the precision and effectiveness of medical interventions.

Aktiia

Series A in 2024
Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

TORTUS AI

Seed Round in 2024
TORTUS AI creates and operates an online tool using artificial intelligence for the healthcare industry. It aims to eliminate human error in medicine through clinician co-working with AI. It provides an AI agent for healthcare, a digital worker that can take over all digital tasks from a clinician such as documentation, requesting tests, access and summarizing patient information. Tortus AI was founded in 2022 and is based in London, England.

Daedalus

Series A in 2024
Daedalus is a contract manufacturing company that specializes in precision parts for the CNC industry. It leverages advanced robotics and artificial intelligence to create reconfigurable production capacity, allowing for instant retooling to accommodate various manufacturing needs. The company offers a software system that enhances manufacturing efficiency and ensures high reliability and transparency throughout the production process. Daedalus is equipped to handle a wide range of production scales, from prototypes to large-scale manufacturing, thereby supporting diverse customer requirements with agility in both process and part complexity.

Rejuvenation Technologies

Seed Round in 2023
Rejuvenation Technologies Inc. is a biotechnology company based in Mountain View, California, focused on developing nucleoside-modified telomerase reverse transcriptase messenger RNA to extend telomeres and promote human health. The company's innovative approach involves delivering a telomere extender that encodes telomerase reverse transcriptase, which transiently boosts telomerase activity in cells. This technology aims to enhance the proliferative capacity of cells, potentially addressing age-related diseases and conditions in various medical fields, including hepatic, pulmonary, and immunology. Additionally, Rejuvenation Technologies offers a range of cell therapies that encompass tissue engineering, cell transplants, skin grafts, immunotherapy, and regenerative medicine. Established in 2016, the company is dedicated to advancing solutions in regenerative health.

SiPhox Health

Series A in 2023
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

SiPhox Health

Seed Round in 2023
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

TORTUS AI

Seed Round in 2023
TORTUS AI creates and operates an online tool using artificial intelligence for the healthcare industry. It aims to eliminate human error in medicine through clinician co-working with AI. It provides an AI agent for healthcare, a digital worker that can take over all digital tasks from a clinician such as documentation, requesting tests, access and summarizing patient information. Tortus AI was founded in 2022 and is based in London, England.

Tachyon

Series A in 2023
Tachyon Therapeutics is a biotechnology company focused on developing innovative therapeutics for cancer treatment. The firm specializes in creating selective compounds that target significant drug targets within cancer biology, employing advanced methodologies in molecular cancer biology, epigenetics, and cancer stem cell biology. Currently, Tachyon is conducting Phase 1 clinical trials to evaluate the safety, pharmacokinetics, and anti-tumor effectiveness of its lead compound, TACH101, in patients with advanced cancer. The company's research and development efforts aim to unlock new pathways for treating challenging cancer types, ensuring that its programs are advanced in a timely and scientifically rigorous manner.

Daedalus

Seed Round in 2023
Daedalus is a contract manufacturing company that specializes in precision parts for the CNC industry. It leverages advanced robotics and artificial intelligence to create reconfigurable production capacity, allowing for instant retooling to accommodate various manufacturing needs. The company offers a software system that enhances manufacturing efficiency and ensures high reliability and transparency throughout the production process. Daedalus is equipped to handle a wide range of production scales, from prototypes to large-scale manufacturing, thereby supporting diverse customer requirements with agility in both process and part complexity.

Synchron

Series C in 2022
Synchron is a medical technology company focused on developing innovative brain-computer interface solutions. It manufactures an implantable device known as the stentrode, which is delivered to the brain via a catheter. This minimally invasive device is embedded with electrode arrays that can interpret neuronal signals and modulate neural activity in targeted areas. By enabling patients with motor impairments to control digital devices, prosthetics, and other assistive technologies through thought, Synchron aims to enhance the quality of life for individuals with disabilities.

AliveCor

Series F in 2022
AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Mirvie

Series B in 2022
Mirvie is a biotech company focused on developing non-invasive tests aimed at improving maternal-fetal health. Founded in 2018 and based in South San Francisco, California, Mirvie offers a medical diagnostic platform that provides actionable insights for mothers and families throughout their pregnancy journey. The company's innovative predictive tests help medical practitioners identify at-risk pregnancies, allowing for timely interventions and enhanced management of pregnancy-related concerns. By prioritizing safety and health, Mirvie seeks to empower families with the information necessary for better pregnancy outcomes.

Daedalus

Seed Round in 2021
Daedalus is a contract manufacturing company that specializes in precision parts for the CNC industry. It leverages advanced robotics and artificial intelligence to create reconfigurable production capacity, allowing for instant retooling to accommodate various manufacturing needs. The company offers a software system that enhances manufacturing efficiency and ensures high reliability and transparency throughout the production process. Daedalus is equipped to handle a wide range of production scales, from prototypes to large-scale manufacturing, thereby supporting diverse customer requirements with agility in both process and part complexity.

Vicarious Surgical

Post in 2021
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company focuses on developing advanced robotic systems that enhance the efficiency of minimally invasive surgical procedures. Its innovative surgical robot combines virtual reality with human-like robotics, allowing for greater precision and control during complex surgeries. Designed for abdominal access, the Vicarious Surgical Robotic System features 3D visualization and operates through a single port, which minimizes invasiveness and promotes faster patient recovery. This compact and portable system can be easily integrated into existing operating rooms, aiming to improve patient outcomes and reduce healthcare costs.

Synchron

Series B in 2021
Synchron is a medical technology company focused on developing innovative brain-computer interface solutions. It manufactures an implantable device known as the stentrode, which is delivered to the brain via a catheter. This minimally invasive device is embedded with electrode arrays that can interpret neuronal signals and modulate neural activity in targeted areas. By enabling patients with motor impairments to control digital devices, prosthetics, and other assistive technologies through thought, Synchron aims to enhance the quality of life for individuals with disabilities.

Clear Labs

Series C in 2021
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dxâ„¢ and Clear Safetyâ„¢, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Hello Heart

Series C in 2021
Hello Heart Inc. is a health technology company that offers a comprehensive application designed to help individuals manage their blood pressure effectively. Founded in 2013 and based in Redwood City, California, the company provides users with a wireless blood pressure monitor paired with a smartphone application that delivers real-time, personalized health tips. The application is particularly aimed at individuals with high blood pressure, empowering them to understand and improve their heart health. By facilitating self-management and promoting behavior change, Hello Heart seeks to prevent serious health risks associated with hypertension, which is a major cost factor for employers. The program is clinically based, ensuring that users receive reliable guidance in an engaging manner.

Overture Life

Series B in 2021
Overture Life, Inc. is a biotechnology company established in 2017 and headquartered in New York, New York. The company specializes in developing robotic technology and medical devices aimed at automating the in vitro fertilization (IVF) process. Overture Life's innovations include novel embryo testing methodologies and automated cryopreservation services, which help fertility clinics identify viable embryos prior to implantation. By streamlining the IVF process, Overture Life aims to make artificial insemination more accessible, reduce costs, optimize resource use, and improve success rates for practitioners and patients alike.

Docbot

Series A in 2021
Docbot, Inc. is an artificial intelligence technology company based in Irvine, California, that specializes in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices, offering a clinical decision support system that aggregates patient information and provides cloud analytics for healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which focuses on real-time image analysis and automated reporting. This platform is designed to detect colorectal cancer and other gastrointestinal conditions by integrating various data sources from imaging systems and pathology requisitions. Docbot aims to enhance patient care and streamline clinical workflows, ultimately reducing cancer risks and improving outcomes for patients in the gastrointestinal specialty.

Apton Biosystems

Series A in 2021
Apton Biosystems, Inc., founded in 2012 and located in Pleasanton, California, operates within the biotechnology industry, focusing on advanced medical technology. The company has developed an innovative optical system for sequencing and protein detection that utilizes super-resolution techniques. This technology allows for the assessment of molecules situated closer than the wavelength of light, facilitating multi-omic sequencing and single-molecule protein detection. Apton's solutions aim to enhance biomarker discovery, enable early disease detection, and support therapeutic monitoring, thereby contributing to advances in preventive health and precision medicine.

StimScience

Seed Round in 2021
StimScience is an Electroceuticals company based in Berkeley, California, specializing in transcranial electrical stimulation (tES) technologies, including transcranial direct current stimulation, transcranial alternating current stimulation, and transcranial random noise stimulation. Founded in 2017, the company focuses on translating neuroscience and sleep research into practical products and services aimed at improving sleep quality and overall brain health. Their NeuroMod tXES system allows users to create custom waveforms for tES applications. StimScience's team comprises leading experts in sleep research and non-invasive brain stimulation, including prominent scientists and former employees from major tech companies. The company is developing Somnee, a diagnostic and therapeutic product designed to enhance sleep onset and quality. Recognizing the critical role of sleep in mental health, memory, and physical fitness, StimScience aims to address the widespread issue of sleep dissatisfaction affecting a significant portion of the adult population.

Rightway

Series C in 2021
Rightway is a technology and services company focused on simplifying healthcare for clients and their members. The company develops care navigation and pharmacy benefit management (PBM) solutions aimed at reducing healthcare spending by guiding members toward optimal care and therapies. Rightway's mission centers on using guidance and advocacy to lower costs and improve healthcare outcomes by aligning incentive models and integrating clinicians into the care journey. Its modern care navigation technology offers clinical guidance at a lower cost compared to traditional solutions. Additionally, Rightway's innovative PBM model ensures that every prescription is directed towards the lowest net cost, thereby minimizing expenses for members. The company’s transparent approach to pharmacy benefits is unique in that it incorporates care navigation, enhancing the overall member experience and engagement while addressing total cost-of-care.

Earli

Series A in 2021
Earli is a company focused on developing innovative cancer treatment devices that utilize synthetic biomarkers for early cancer detection. The company's approach involves a novel gene therapy technique known as Synthetic Biopsy, which prompts cancer cells to produce synthetic, non-human biomarkers. These biomarkers can be detected through various means, including blood, urine, or breath, allowing for timely tracking and treatment of cancer. By facilitating the early identification of cancer when it is still homogeneous, Earli aims to significantly enhance survival rates. Their technology not only aids in detection but is also applicable for therapeutic interventions, thereby personalizing treatment and improving patient outcomes.

AliveCor

Series E in 2020
AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Advanced Chemotherapy Technologies

Series A in 2020
Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.

Invoy

Series A in 2020
Invoy is a company focused on providing personalized nutrition and wellness services through innovative monitoring medical devices. By utilizing science, data, and artificial intelligence, Invoy's technology captures real-time data on individual metabolism, allowing for tailored nutritional recommendations. The company aims to enhance individual health and weight loss goals by addressing the unique body chemistry of each person. With an emphasis on affordability, Invoy offers breath analyzers for medical applications, enabling users to effectively monitor their health and optimize their wellness journey.

SiPhox Health

Seed Round in 2020
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Vicarious Surgical

Series A in 2020
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company focuses on developing advanced robotic systems that enhance the efficiency of minimally invasive surgical procedures. Its innovative surgical robot combines virtual reality with human-like robotics, allowing for greater precision and control during complex surgeries. Designed for abdominal access, the Vicarious Surgical Robotic System features 3D visualization and operates through a single port, which minimizes invasiveness and promotes faster patient recovery. This compact and portable system can be easily integrated into existing operating rooms, aiming to improve patient outcomes and reduce healthcare costs.

Caption Health

Series B in 2020
Caption Health, Inc. is a technology company that specializes in artificial intelligence-driven software solutions for ultrasound examinations. Founded in 2013 and headquartered in Brisbane, California, the company offers Caption AI, a system designed to assist healthcare providers in acquiring and interpreting ultrasound images. This software provides real-time guidance during exams, automates quality assessments, and facilitates the interpretation of ultrasound results, enabling practitioners to capture high-quality diagnostic images more efficiently. As the adoption of the Caption AI platform grows, Caption Health plans to enhance its technology and expand its clinical capabilities, aiming to integrate its solutions into a wider range of healthcare settings.

Kernel

Series C in 2020
Kernel, a neuroscience company founded in 2016 and headquartered in Los Angeles, California, develops advanced brain-recording technologies aimed at enhancing human cognition. The company specializes in creating a non-invasive brain interface that captures neural signals with quality comparable to traditional imaging methods like fMRI and MEG, while being as user-friendly as EEG. Kernel's primary focus is on addressing dysfunctions linked to neurodegenerative diseases, offering neuroprosthetics that can mimic, repair, and improve cognitive functions. Additionally, the company provides access to brain imaging devices that enable remote experimentation, thereby furthering the understanding and treatment of neurological disorders.

Siren

Series B in 2020
Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.

Clear Labs

Venture Round in 2020
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dxâ„¢ and Clear Safetyâ„¢, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Daedalus

Pre Seed Round in 2020
Daedalus is a contract manufacturing company that specializes in precision parts for the CNC industry. It leverages advanced robotics and artificial intelligence to create reconfigurable production capacity, allowing for instant retooling to accommodate various manufacturing needs. The company offers a software system that enhances manufacturing efficiency and ensures high reliability and transparency throughout the production process. Daedalus is equipped to handle a wide range of production scales, from prototypes to large-scale manufacturing, thereby supporting diverse customer requirements with agility in both process and part complexity.

HeartVista

Series A in 2020
HeartVista is a medical technology company that provides one-click diagnostic imaging. It brought in machine learning to make the scanning process faster, easier, and more consistent. Its platform leverages existing scanners and contains all of the mri tools needed for a comprehensive cardiac examination, with just one click.

Hello Heart

Series B in 2019
Hello Heart Inc. is a health technology company that offers a comprehensive application designed to help individuals manage their blood pressure effectively. Founded in 2013 and based in Redwood City, California, the company provides users with a wireless blood pressure monitor paired with a smartphone application that delivers real-time, personalized health tips. The application is particularly aimed at individuals with high blood pressure, empowering them to understand and improve their heart health. By facilitating self-management and promoting behavior change, Hello Heart seeks to prevent serious health risks associated with hypertension, which is a major cost factor for employers. The program is clinically based, ensuring that users receive reliable guidance in an engaging manner.

Overture Life

Venture Round in 2019
Overture Life, Inc. is a biotechnology company established in 2017 and headquartered in New York, New York. The company specializes in developing robotic technology and medical devices aimed at automating the in vitro fertilization (IVF) process. Overture Life's innovations include novel embryo testing methodologies and automated cryopreservation services, which help fertility clinics identify viable embryos prior to implantation. By streamlining the IVF process, Overture Life aims to make artificial insemination more accessible, reduce costs, optimize resource use, and improve success rates for practitioners and patients alike.

Docbot

Seed Round in 2019
Docbot, Inc. is an artificial intelligence technology company based in Irvine, California, that specializes in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices, offering a clinical decision support system that aggregates patient information and provides cloud analytics for healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which focuses on real-time image analysis and automated reporting. This platform is designed to detect colorectal cancer and other gastrointestinal conditions by integrating various data sources from imaging systems and pathology requisitions. Docbot aims to enhance patient care and streamline clinical workflows, ultimately reducing cancer risks and improving outcomes for patients in the gastrointestinal specialty.

Vicarious Surgical

Series B in 2019
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company focuses on developing advanced robotic systems that enhance the efficiency of minimally invasive surgical procedures. Its innovative surgical robot combines virtual reality with human-like robotics, allowing for greater precision and control during complex surgeries. Designed for abdominal access, the Vicarious Surgical Robotic System features 3D visualization and operates through a single port, which minimizes invasiveness and promotes faster patient recovery. This compact and portable system can be easily integrated into existing operating rooms, aiming to improve patient outcomes and reduce healthcare costs.

StimScience

Seed Round in 2019
StimScience is an Electroceuticals company based in Berkeley, California, specializing in transcranial electrical stimulation (tES) technologies, including transcranial direct current stimulation, transcranial alternating current stimulation, and transcranial random noise stimulation. Founded in 2017, the company focuses on translating neuroscience and sleep research into practical products and services aimed at improving sleep quality and overall brain health. Their NeuroMod tXES system allows users to create custom waveforms for tES applications. StimScience's team comprises leading experts in sleep research and non-invasive brain stimulation, including prominent scientists and former employees from major tech companies. The company is developing Somnee, a diagnostic and therapeutic product designed to enhance sleep onset and quality. Recognizing the critical role of sleep in mental health, memory, and physical fitness, StimScience aims to address the widespread issue of sleep dissatisfaction affecting a significant portion of the adult population.

Siren

Series A in 2018
Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.

Clear Labs

Series B in 2018
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dxâ„¢ and Clear Safetyâ„¢, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Eva

Venture Round in 2018
Higia Technologies, founded in 2016 and based in Mexico City, develops EVA, a wearable device aimed at assessing breast cancer risk. This non-invasive device features tactile sensors that map the breast's surface and surrounding areas, enabling women to monitor changes in breast temperature, size, and weight. Equipped with biosensors, EVA continuously tracks relevant information, providing users with accessible tools for breast health management.

Openwater

Seed Round in 2018
Openwater is a San Francisco-based startup founded in 2016 that focuses on developing advanced medical technology aimed at diagnosing and treating diseases at the cellular level. The company has created a wearable device that leverages novel optoelectronic technology to offer high-resolution imaging capabilities, effectively replacing traditional MRI methods. By utilizing LCDs with small pixels, Openwater's device generates holographic images that minimize scattering and achieve MRI-like resolution. This innovation enables physicians to diagnose and treat diseases by targeting individual cells while preserving the surrounding tissue, thereby enhancing the precision and effectiveness of medical interventions.

Zebra Medical Vision

Series C in 2018
Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

Vicarious Surgical

Series A in 2018
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company focuses on developing advanced robotic systems that enhance the efficiency of minimally invasive surgical procedures. Its innovative surgical robot combines virtual reality with human-like robotics, allowing for greater precision and control during complex surgeries. Designed for abdominal access, the Vicarious Surgical Robotic System features 3D visualization and operates through a single port, which minimizes invasiveness and promotes faster patient recovery. This compact and portable system can be easily integrated into existing operating rooms, aiming to improve patient outcomes and reduce healthcare costs.

Siren

Seed Round in 2018
Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.

Mirvie

Series A in 2018
Mirvie is a biotech company focused on developing non-invasive tests aimed at improving maternal-fetal health. Founded in 2018 and based in South San Francisco, California, Mirvie offers a medical diagnostic platform that provides actionable insights for mothers and families throughout their pregnancy journey. The company's innovative predictive tests help medical practitioners identify at-risk pregnancies, allowing for timely interventions and enhanced management of pregnancy-related concerns. By prioritizing safety and health, Mirvie seeks to empower families with the information necessary for better pregnancy outcomes.

Olive

Series C in 2017
Olive deploys the AI workforce built specifically for healthcare, delivering hospitals and health systems increased revenue, reduced costs, and increased capacity. Olive automates repetitive, high-volume tasks and workflows, monitoring their performance, identifying improvements, and finding opportunities for new work. Olive gives power back to providers through her ever-growing, unparalleled intelligence made up of shared memories, collective wisdom, and global awareness, learning like a network so hospitals never have to solve the same problem twice. Olive was founded in 2012 and is headquartered in Columbus, Ohio.

Catalia Health

Seed Round in 2017
Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.

Guardant Health

Series E in 2017
Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

Catalia Health

Seed Round in 2017
Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.

Ontera

Series A in 2017
Ontera Inc. specializes in the development of innovative single molecule detection and genome analysis platforms utilizing biochemistry and silicon nanopore chip technology. The company offers a range of products, including the SAM device, which facilitates the detection and quantification of various targets such as acids, proteins, and small molecules across different applications in plants, animals, and humans. Additionally, Ontera provides the DUO Nano platform for genome mapping, structural variant analysis, epigenetics, and direct strand sequencing. Its solutions cater to diverse sectors, including agriculture, human and animal diagnostics, law enforcement, and drug discovery, among others. Founded in 2011 and headquartered in Santa Cruz, California, Ontera was previously known as Two Pore Guys, Inc. before rebranding in May 2019. The company aims to enhance point-of-care testing and advance the field of third-generation sequencing.

Medisas

Series A in 2016
Medisas, Inc. offers a cloud-based service that facilitates the transfer of medical information among healthcare professionals during shift changes. Based in the United States, the company develops record-keeping software aimed at improving patient care and safety. This software allows clinicians to document and share critical information related to shift changes, patient transfers, and discharges across various devices. By streamlining communication among healthcare providers, Medisas enhances organizational efficiency and supports better patient outcomes throughout the care process. The team comprises experienced clinicians, engineers, and designers dedicated to transforming hospital software to meet the evolving needs of healthcare organizations.

Clear Labs

Series B in 2016
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dxâ„¢ and Clear Safetyâ„¢, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Caption Health

Series A in 2016
Caption Health, Inc. is a technology company that specializes in artificial intelligence-driven software solutions for ultrasound examinations. Founded in 2013 and headquartered in Brisbane, California, the company offers Caption AI, a system designed to assist healthcare providers in acquiring and interpreting ultrasound images. This software provides real-time guidance during exams, automates quality assessments, and facilitates the interpretation of ultrasound results, enabling practitioners to capture high-quality diagnostic images more efficiently. As the adoption of the Caption AI platform grows, Caption Health plans to enhance its technology and expand its clinical capabilities, aiming to integrate its solutions into a wider range of healthcare settings.

Vicarious Surgical

Venture Round in 2016
Vicarious Surgical Inc. is a robotics company based in Charlestown, Massachusetts, established in 2014. The company focuses on developing advanced robotic systems that enhance the efficiency of minimally invasive surgical procedures. Its innovative surgical robot combines virtual reality with human-like robotics, allowing for greater precision and control during complex surgeries. Designed for abdominal access, the Vicarious Surgical Robotic System features 3D visualization and operates through a single port, which minimizes invasiveness and promotes faster patient recovery. This compact and portable system can be easily integrated into existing operating rooms, aiming to improve patient outcomes and reduce healthcare costs.

Zebra Medical Vision

Series B in 2016
Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

Olive

Series C in 2016
Olive deploys the AI workforce built specifically for healthcare, delivering hospitals and health systems increased revenue, reduced costs, and increased capacity. Olive automates repetitive, high-volume tasks and workflows, monitoring their performance, identifying improvements, and finding opportunities for new work. Olive gives power back to providers through her ever-growing, unparalleled intelligence made up of shared memories, collective wisdom, and global awareness, learning like a network so hospitals never have to solve the same problem twice. Olive was founded in 2012 and is headquartered in Columbus, Ohio.

Guardant Health

Series D in 2016
Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

Clear Labs

Series A in 2015
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dxâ„¢ and Clear Safetyâ„¢, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Klarismo

Seed Round in 2015
Klarismo Limited, based in London, specializes in body analysis through advanced 3D body scanning technology. The company provides health-conscious consumers and amateur athletes with a unique service that transforms full-body magnetic resonance imaging (MRI) scans into detailed 3D virtual models. These models offer accurate volumetric measurements of muscle and fat tissues, allowing users to explore and understand their body composition in depth. With annotated information, individuals can learn about different body parts and monitor changes over time, making it easier to assess the effectiveness of their fitness or diet regimens. Klarismo also supports private medical imaging centers by optimizing their asset utilization and contributing to a database of full-body MRI scans for medical research. Founded in 2014, Klarismo is committed to enhancing users' health and fitness insights through innovative technology.

Catalia Health

Seed Round in 2015
Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.

Olive

Series B in 2015
Olive deploys the AI workforce built specifically for healthcare, delivering hospitals and health systems increased revenue, reduced costs, and increased capacity. Olive automates repetitive, high-volume tasks and workflows, monitoring their performance, identifying improvements, and finding opportunities for new work. Olive gives power back to providers through her ever-growing, unparalleled intelligence made up of shared memories, collective wisdom, and global awareness, learning like a network so hospitals never have to solve the same problem twice. Olive was founded in 2012 and is headquartered in Columbus, Ohio.

Zebra Medical Vision

Seed Round in 2015
Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

Apton Biosystems

Venture Round in 2015
Apton Biosystems, Inc., founded in 2012 and located in Pleasanton, California, operates within the biotechnology industry, focusing on advanced medical technology. The company has developed an innovative optical system for sequencing and protein detection that utilizes super-resolution techniques. This technology allows for the assessment of molecules situated closer than the wavelength of light, facilitating multi-omic sequencing and single-molecule protein detection. Apton's solutions aim to enhance biomarker discovery, enable early disease detection, and support therapeutic monitoring, thereby contributing to advances in preventive health and precision medicine.

Guardant Health

Series C in 2015
Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

Caption Health

Seed Round in 2015
Caption Health, Inc. is a technology company that specializes in artificial intelligence-driven software solutions for ultrasound examinations. Founded in 2013 and headquartered in Brisbane, California, the company offers Caption AI, a system designed to assist healthcare providers in acquiring and interpreting ultrasound images. This software provides real-time guidance during exams, automates quality assessments, and facilitates the interpretation of ultrasound results, enabling practitioners to capture high-quality diagnostic images more efficiently. As the adoption of the Caption AI platform grows, Caption Health plans to enhance its technology and expand its clinical capabilities, aiming to integrate its solutions into a wider range of healthcare settings.

Guardant Health

Series B in 2014
Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

SLD Laser

Series A in 2013
SLD Laser specializes in the development and commercialization of advanced visible laser light sources for various applications, including automotive, mobility, specialty lighting, and consumer products. The company utilizes innovative semi-polar GaN laser technology to enhance performance and reliability. Its laser light sources are ISO 9001 certified and comply with automotive standards, ensuring safety and quality across its products. With facilities in Santa Barbara and Fremont, California, SLD Laser's high luminance LaserLight sources are UL and IEC safety certified and find applications in diverse fields such as entertainment, projection and augmented/virtual reality displays, biomedical instrumentation, and industrial imaging and material processing.

Embrace Global

Series A in 2013
Embrace Global is a healthcare technology company based in Bengaluru, India, focused on developing affordable medical devices for emerging markets. The company is known for its flagship product, the Embrace Nest, a portable infant warmer designed to assist low birth-weight and premature babies. This innovative solution offers a cost-effective alternative to traditional incubators, priced at less than 1% of current options, thereby addressing the critical need to reduce mortality rates among the estimated 20 million premature-birth-weight infants who die each year. In addition to its existing products, Embrace Global engages in research and development to create new low-cost innovations aimed at improving maternal and child health.

Medisas

Seed Round in 2013
Medisas, Inc. offers a cloud-based service that facilitates the transfer of medical information among healthcare professionals during shift changes. Based in the United States, the company develops record-keeping software aimed at improving patient care and safety. This software allows clinicians to document and share critical information related to shift changes, patient transfers, and discharges across various devices. By streamlining communication among healthcare providers, Medisas enhances organizational efficiency and supports better patient outcomes throughout the care process. The team comprises experienced clinicians, engineers, and designers dedicated to transforming hospital software to meet the evolving needs of healthcare organizations.

CellScope

Seed Round in 2012
CellScope, Inc. develops innovative imaging devices that facilitate at-home disease diagnosis through smartphone technology. Founded in 2010 and based in Menlo Park, California, the company offers a range of products, including a clip-on otoscope and a dermascope, which allow users to capture high-resolution images of the ear and skin. These devices enable pediatricians and patients to create visual records for better tracking of conditions, particularly in remote settings. CellScope's technology enhances telemedicine by providing clinicians with the ability to share images and videos securely, which aids in diagnosing pediatric ear infections and skin diseases. By improving remote diagnosis, CellScope aims to streamline healthcare delivery, reduce unnecessary antibiotic prescriptions, and support effective monitoring of health conditions from home.

AliveCor

Series B in 2012
AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

HeartVista

Seed Round in 2012
HeartVista is a medical technology company that provides one-click diagnostic imaging. It brought in machine learning to make the scanning process faster, easier, and more consistent. Its platform leverages existing scanners and contains all of the mri tools needed for a comprehensive cardiac examination, with just one click.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.